Literature DB >> 10218880

Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats.

A Samii1, J Unger, W Lange.   

Abstract

Vascular alterations of peripheral nerves occuring after mechanical injury or in metabolic disorders are well described. It is thought that vascular endothelial growth factor (VEGF), a potent growth factor for angiogenesis, also plays an important role for regeneration of nervous tissue. We used a rat model of type I diabetes (streptozotozin-induced) with sensory neuropathy and with chronic hyperglycemia over 12 weeks. A monoclonal antibody to VEGF was used for immunohistochemistry of sciatic nerves and dorsal root ganglia (DRG). Intense VEGF staining was detected in cell bodies and nerve fibers of animals with chronic diabetes. Healthy control groups expressed no or very little VEGF and animals treated with insulin to prevent neuropathy and severe hyperglycemia showed significantly lower immunostaining for VEGF. After application of nerve growth factor (NGF), which is known to improve axonal and Schwann cell regeneration, a markedly decreased expression of VEGF was seen in diabetic animals. In contrast, enhanced VEGF staining was noted in NGF-treated healthy controls of the same age and body weight as the diabetic rats. Similar findings were made in diabetic animals treated with both, insulin and NGF. We conclude that functional alteration of peripheral nerves causes up-regulation of VEGF in Schwann cells and neurons. With functional restitution of nervous tissue, i.e. under insulin and/or NGF treatment VEGF expression decreases significantly. Additionally, NGF may stimulate VEGF in normal controls. The production of VEGF may play a role in complete nerve regeneration and its regulation may reflect the functional state of peripheral nerves.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218880     DOI: 10.1016/s0304-3940(99)00064-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  26 in total

Review 1.  Glucose, VEGF-A, and diabetic complications.

Authors:  L E Benjamin
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Can VEGF reverse diabetic neuropathy in human subjects?

Authors:  A Veves; G L King
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  Cardiovascular actions of neurotrophins.

Authors:  Andrea Caporali; Costanza Emanueli
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

4.  Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy.

Authors:  Mitra Tavakoli; Omar Asghar; Uazman Alam; Ioannis N Petropoulos; Hassan Fadavi; Rayaz A Malik
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

5.  HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy.

Authors:  M Chattopadhyay; D Krisky; D Wolfe; J C Glorioso; M Mata; D J Fink
Journal:  Gene Ther       Date:  2005-09       Impact factor: 5.250

6.  Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors.

Authors:  L Calza; L Giardino; A Giuliani; L Aloe; R Levi-Montalcini
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

Review 7.  New insights into molecular mechanisms of diabetic kidney disease.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  Am J Kidney Dis       Date:  2014-02       Impact factor: 8.860

8.  Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy.

Authors:  Xialin Liu; Yongjun Li; Yizhi Liu; Yan Luo; Dingding Wang; Brian H Annex; Pascal J Goldschmidt-Clermont
Journal:  Am J Pathol       Date:  2009-11-30       Impact factor: 4.307

Review 9.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

10.  Engineered zinc finger protein-mediated VEGF-a activation restores deficient VEGF-a in sensory neurons in experimental diabetes.

Authors:  Elizabeth J Pawson; Beatriz Duran-Jimenez; Richard Surosky; Heather E Brooke; S Kaye Spratt; David R Tomlinson; Natalie J Gardiner
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.